Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.34 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.33 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.33 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8234440 | 0.92 | UTS2R (0.38) | BACE1UTS2RCTSDGAAMAPT | |
| Trifluoroacetic Acid SCHEMBL5001884 | 0.89 | MEN1 (0.36) | BACE1MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL5001889 | 0.87 | PARP1 (0.37) | BACE1KDM1AORAI1CTSDGAA | |
| Trifluoroacetic Acid SCHEMBL5007677 | 0.87 | UTS2R (0.37) | BACE1KDM1AUTS2RORAI1KCNJ6 | |
| Trifluoroacetic Acid SCHEMBL5001625 | 0.82 | BACE1 (0.35) | BACE1KDM1AORAI1CTSD | |
| SCHEMBL5002065 | 0.82 | PARP1 (0.40) | BACE1CTSD | |
| Trifluoroacetic Acid SCHEMBL5001600 | 0.81 | BACE1 (0.46) | BACE1 | |
| SCHEMBL14010655 | 0.81 | NOS3 (0.38) | BACE1GAAMAPTSMN1; SMN2MEN1 | |
| Trifluoroacetic Acid SCHEMBL5001603 | 0.79 | BACE1 (0.36) | BACE1KDM1ACTSD | |
| SCHEMBL5026581 | 0.78 | MAPT (0.34) | BACE1UTS2RORAI1KCNJ6KCNJ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101360714-A | Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies | ASTRAZENECA AB (SE) | 2009-02-04 | — | — | CN | claimed |
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| CN-101360714-A | Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies | ASTRAZENECA AB (SE) | 2009-02-04 | — | — | CN | disclosed |
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| EP-1957462-A2 | NOVEL 2-AMINO-HETEROCYCLES UDEFUL IN THE TREATMENT OF ABETA-RELATED PATHOLOGIES | Astra Zeneca AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007058583-A2 | NOVEL 2-AMINO-HETEROCYCLES USEFUL IN THE TREATMENT OF ABETA-RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | PSEN2, APP, PSEN1 | BACE1 4/4885KDM1A 3884/4885UTS2R 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.